<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijbi.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 5 ISSUE Issue 1</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<description>
International-Journal-of-Biomedical-Investigation: VOLUME Volume 5 ISSUE Issue 1, Jan-June 2022
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>International-Journal-of-Biomedical-Investigation-ISSUE VOLUME Volume 5 ISSUE Issue 1</title>
<link>http://ijbi.edwiserinternational.com/rss-feed.php</link>
<url>http://ijbi.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>A-Comparative-Study-to-Assess-the-Prevalence-and-Behaviour-Regarding-Covid-19-Among-Public-at-Selected-Rural-and-Urban-Areas-Khammam-Telangana</title>
		<pubDate>23-Jun-2022</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/r4hF5d.pdf</link>
		<author>Elluri-Venaktesh-and-G-Asha-Kumari</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[A comparative study to assess the prevalence and behaviour regarding Covid -19 among public at selected rural and urban areas, Khammam, Telangana. Th objectives were to assess the prevalence of Covid-19 among rural and urban public, to assess the behaviour regarding Covid-19 among rural and urban public. To develop and distribute an information booklet on appropriate behavior regarding Covid- 19 to rural and urban public. Methodology: A quantitative survey approach and Cross-sectional comparative descriptive design was used for this study. The study was conducted at rural public of Raghunadhapalem and urban public of Sambani nagar, it is one of the urban areas of Khammam, Telangana. The sample comprised of 200 (100 from Urban and 100 from Rural) and sample was selected by Non-Probability Convenience Sampling Technique. The data was collected by interview technique and tool use for the study was structured Interview schedule. Results: The results revealed that 200 (100 from urban and 100 from rural) Period prevalence was calculated according to the census available at sub centre on 30th August 2021.The period prevalence in urban public at Sambani nagar was 4.5 and in rural public at Raghunadhapalem was 4. The period prevalence was almost same at both the places. When it comes to appropriate behaviour for Covid-19 pandemic situation the urban public are following the preventive measures 100% when compared to the rural public which is only 43.3%.Conclusion: The study concludes that the period prevalence is almost same with slight difference in urban and rural public. When it comes to appropriate behaviour for Covid-19 pandemic situation the urban public are following the preventive measures when compared to the rural public. So the rural public need to be given more awareness programs regarding appropriate behavior to prevent spread of Covid-19.]]>}</description>
		</item><item>
		<title>Effect-of-Creatine-Supplementation-on-the-Muscular-Inflammation-and-Muscle-Atrophy-in-High-Fat-High-Fructose-Fed-Obese-Growing-Rats</title>
		<pubDate>17-Jun-2022</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/65xkmd.pdf</link>
		<author>Oh-S-Kwon-D-Park-J-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Objective: This study aimed to investigate effects of creatine supplementation on high-fat high-fructose fed obese rats. Twenty-four six-week-old male Sprague-Dawley rats were randomly divided into three groups (n=8 each): control sedentary group (CD), high-fat high-fructose diet group (HD), and creatine-supplemented high-fat high-fructose diet group (CHD). Methodology: The CD group was supplemented with AIN-76G diet, and a high-fat high-fructose diet for HD and CHD groups was substituted with 5% corn oil fat to 35% lard. The CHD group was supplemented with 2% creatine. The total soleus muscle protein was extracted and prepared according to the procedure mentioned by Baghirova et al. for muscle cytokine assay and western blotting. Result: After eight weeks of the experimental period, weights of the soleus muscle in the HD and CHD groups were significantly lower than that in the CD group. In addition, levels of proinflammatory cytokines interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)- in the HD groups were significantly higher than those in the CD group. In contrast, IL-1, IL-6 concentrations in the CHD group were significantly lower than those in the HD group and irisin levels of HD and CHD group were significantly lower than those in the CD group. Moreover, levels of muscle protein degradation factors [Muscle RING-finger protein-1 (MuRF1) and atrogin-1] were significantly higher in the HD and CHD groups than those in the CD group. Conclusion: From these results, it was concluded that creatine supplementation attenuates the inflammation of skeletal muscle via pro-inflammatory cytokines; however, it has no significant role in preventing muscular atrophy in high-fat high-fructose fed obese rats.]]>}</description>
		</item><item>
		<title>Dostarlimab-A-Miracle-Drug-Against-Cancer-Current-Knowledge-and-On-going-Clinical-Trials</title>
		<pubDate>04-Jul-2022</pubDate>
<link>http://ijbi.edwiserinternational.com/admin/uploads/tp1sPr.pdf</link>
		<author>Jahangir-MA-Kumar-N-Shahab-MS</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Cancer stands as one of the leading causes of death globally. Its socio-economic burden is increasing day by day. There is no defined treatment strategy for cancer. In most of the cases a combinatorial therapy approach is utilised which includes surgery, chemotherapy, immune therapy, radiation therapy etc. Immune checkpoints are a revolutionary discovery in cancer immunotherapy. Dostarlimab is an anti-programmed cell death protein-1 (PD-1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells. PD-1 is an immune checkpoint receptor expressed by T-cells which has shown to suppress cancer-specific immune responses. In this article we provide the recent known information regarding dostarlimab along with currently undergoing 44 clinical trials globally with its title, conditions, interventions, and outcome measures.]]>}</description>
		</item></channel>